Boston Scientific Corp. (BSX)

35.80
NYSE : Health Technology
Prev Close 36.98
Day Low/High 35.54 / 36.60
52 Wk Low/High 24.79 / 39.44
Avg Volume 7.51M
Exchange NYSE
Shares Outstanding 1.38B
Market Cap 51.34B
EPS 0.10
P/E Ratio 77.04
Div & Yield N.A. (N.A)
Boston Scientific Prevails In U.S. Edwards Lifesciences Litigation

Boston Scientific Prevails In U.S. Edwards Lifesciences Litigation

Delaware Court Rules Edwards Lifesciences Infringes Boston Scientific Patent

Shire, Abbott Labs May Pace Healthcare Stocks in 2019

Shire, Abbott Labs May Pace Healthcare Stocks in 2019

Healthcare has been the best performing sector of the market this year. Here are three buy-rated stocks to track now.

When Will the Pain End?: Cramer's 'Mad Money' Recap (Tuesday 11/27/18)

When Will the Pain End?: Cramer's 'Mad Money' Recap (Tuesday 11/27/18)

Jim Cramer says most - but not all - stocks are in a bear market. He talks about what's happening with Clorox, Coca-Cola, Verizon, Apple and more.

Analog Devices, MongoDB, Welltower: 'Mad Money' Lightning Round

Analog Devices, MongoDB, Welltower: 'Mad Money' Lightning Round

Jim Cramer takes a look at Analog Devices, MongoDB, Welltower, Ventas, Iridium Communications, Huntington Bancshares, Citigroup, Randgold Resources and more.

Boston Scientific to Buy Britain's BTG for $4.2 Billion

Boston Scientific to Buy Britain's BTG for $4.2 Billion

Boston Scientific offered $10.77 for each BTG share, valuing the company at $4.2 billion.

FAANGs, Retail, Housing, Boston Scientific & Renault - Five Things You Must Know

FAANGs, Retail, Housing, Boston Scientific & Renault - Five Things You Must Know

FAANG stocks are sliding into bear market territory, retail earnings dominate today's corporate calendar, housing starts and building permits will test US rate hike bets, Boston Scientific makes $4.2 billion U.K. play and Carlos Ghosn could be left by the roadside - Five Things You Must Know Before the Bell.

Boston Scientific Announces Recommended Offer To Acquire BTG Plc.

Boston Scientific Announces Recommended Offer To Acquire BTG Plc.

Transaction would expand peripheral interventions portfolio with minimally-invasive treatments for cancers and vascular conditions

Boston Scientific To Participate In Stifel 2018 Healthcare Conference

Boston Scientific To Participate In Stifel 2018 Healthcare Conference

MARLBOROUGH, Mass., Nov.

Boston Scientific Announces Results For Third Quarter 2018

Boston Scientific Announces Results For Third Quarter 2018

MARLBOROUGH, Mass., Oct.

Boston Scientific Prevails In German Edwards Lifesciences Litigation

Boston Scientific Prevails In German Edwards Lifesciences Litigation

Court Rules Edwards Lifesciences' Next-Generation Valve Infringes Boston Scientific Patent and Grants Right to Enjoin Sales in Germany

Boston Scientific Closes Acquisition Of Augmenix, Inc.

Boston Scientific Closes Acquisition Of Augmenix, Inc.

MARLBOROUGH, Mass., Oct.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Boston Scientific Receives U.S. FDA Approval For The Eluvia™ Drug-Eluting Vascular Stent System

Boston Scientific Receives U.S. FDA Approval For The Eluvia™ Drug-Eluting Vascular Stent System

First peripheral vascular interventional technology approved in the U.S. to offer sustained release of antiproliferative drug to treat patients with peripheral artery disease

Boston Scientific Eluvia Drug-Eluting Stent Demonstrates Superior Results In IMPERIAL Trial

Boston Scientific Eluvia Drug-Eluting Stent Demonstrates Superior Results In IMPERIAL Trial

First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries

Boston Scientific Launches LithoVue Empower™ Retrieval Deployment Device

Boston Scientific Launches LithoVue Empower™ Retrieval Deployment Device

New Data at World Congress of Endourology Demonstrate the LithoVue Empower Device Improves OR Experience

Jim Cramer: Here's Why the Market Rally Has Staying Power

Jim Cramer: Here's Why the Market Rally Has Staying Power

For most of this year the market has been led by growth stocks.

Jim Cramer: Valuations Now Have No Relation to Common Sense

Jim Cramer: Valuations Now Have No Relation to Common Sense

Analyst downgrades and mind-boggling P/E ratios do not matter in this current market.

How Boston Scientific Call Prices Rose Eightfold

How Boston Scientific Call Prices Rose Eightfold

The Healthcare sector has seen a revitalization year-to-date, and these investors may have wanted to participate in a continued move higher, risking a fraction of the price of a share in the event they were 'late to the party.'

Boston Scientific Announces Agreement To Acquire Augmenix, Inc.

Boston Scientific Announces Agreement To Acquire Augmenix, Inc.

Acquisition expands portfolio of men's health in-office procedures with adjunctive therapy for prostate cancer patients

3 Biotech Stock Favorites to Bet on Today: Top Analysts

3 Biotech Stock Favorites to Bet on Today: Top Analysts

Follow the experts. These biotech stocks have Wall Street's best analysts getting bullish.

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

It is all about perception, and here are strong names to pick up on market weakness.

TheStreet Quant Rating: A- (Buy)